

## Systemic Toxicity and Cytokine/Acute Phase Protein Levels in Patients After Isolated Limb Perfusion With Tumor Necrosis Factor- $\alpha$ Complicated by High Leakage

Tanja C. Stam, MD, Anton J. G. Swaak, MD, PhD, Mark R. de Vries, MD, Timo L. M. ten Hagen, PhD, and Alexander M. M. Eggermont, MD, PhD

---

**Background:** Since the introduction of high-dose tumor necrosis factor- $\alpha$  (TNF $\alpha$ ) in the setting of isolated limb perfusion (ILP) in the clinic, prevention of leakage to the body of the patient is monitored with great precision for fear of TNF-mediated toxicity. That we observed remarkably little toxicity in patients with and without leakage prompted us to determine patterns of cytokines and acute phase proteins in patients with high leakage and in patients without any leakage.

**Methods:** TNF $\alpha$ , interleukin (IL)-6, IL-8, C-reactive protein, and secretory (s)-phospholipase A<sub>2</sub> were measured at several time points during and after (until 7 days) ILP in 10 patients with a leakage to the systemic circulation varying in percentage from 12% to 65%. As a control, the same measurements, both in peripheral blood and in perfusate, were performed in nine patients without systemic leakage.

**Results:** In patients with systemic leakage, levels of TNF $\alpha$  increased during ILP, reaching values to 277 ng/ml. IL-6 and IL-8 peaked 3 hours after ILP with values significantly higher compared with patients without systemic leakage. C-reactive protein and s-phospholipase A<sub>2</sub> peaked at day 1 in both patient groups, s-phospholipase A<sub>2</sub> with significant higher levels and C-reactive protein, in contrast, with lower levels in the leakage patients.

**Conclusions:** High leakage of TNF $\alpha$  to the systemic circulation, caused by a complicated ILP, led to 10-fold to more than 100-fold increased levels of TNF $\alpha$ , IL-6, and IL-8 in comparison with patients without leakage. The increase of the acute phase proteins was limited. Even when high leakage occurs, this procedure should not lead to fatal complications. The most prominent clinical toxicity was hypotension (grade III in four patients), which was easily corrected. No pulmonary or renal toxicity was observed in any patient. It is our experience that, even in the rare event of significant leakage during a TNF $\alpha$ -based ILP, postoperative toxicity is usually mild and can be easily managed by the use of fluid and, in some cases, vasopressors.

**Key Words:** Isolated limb perfusion—TNF $\alpha$ —Leakage—Toxicity—Secondary cytokine response—Acute phase response.

---

The technique of regional isolated limb perfusion (ILP) with the use of an extracorporeal circuit was pioneered by Creech and co-workers.<sup>1</sup> The advantage of this

treatment modality is that a high dose of cytostatic drug can be delivered to the tumor-bearing extremity without producing systemic side effects. ILP permits regional cytostatic concentrations 15 to 20 times higher than those reached after systemic administration.<sup>2</sup> The standard drug in this setting is melphalan (L-phenyl-alaninemustard). In patients with multiple melanoma in-transit metastases, an ILP with melphalan results in about 50% of the patients in a complete remission.<sup>3</sup> Addition of tumor necrosis factor- $\alpha$  (TNF $\alpha$ ) to melphalan has proven most effective in terms of response rate, yielding a 80% to 90% complete response rate and an overall response of about 100%.<sup>4,5</sup> In locally advanced soft-tissue sarcomas, the use of TNF $\alpha$  in combination with melphalan has

---

Received September 14, 1999; accepted January 14, 2000.

From the Department of Surgical Oncology (TCS, MRdV, TLMtH, AMME), University Hospital Rotterdam-Dr. Daniel den Hoed Cancer Center, and the Department of Rheumatology (AJGS), Zuiderziekenhuis, Rotterdam; and the Department of Autoimmune Diseases (AJGS), Central Laboratory of the Netherlands Red Cross Blood Transfusion Service and Laboratory for Experimental and Clinical Immunology, Amsterdam, The Netherlands.

Address correspondence and reprint requests to: A. M. M. Eggermont, MD, PhD, Department of Surgical Oncology, Dr. Daniel den Hoed Cancer Center, PO Box 5201, 3008 AE Rotterdam, The Netherlands; Fax: +31-10-4391011; E-mail: eggermont@chih.azr.nl

proven remarkably effective in rendering irresectable tumors resectable and thereby preventing amputations.<sup>5,6</sup> The efficacy of TNF against the drug-resistant soft-tissue sarcomas has led to the approval of TNF by the EMEA (European Medicine Evaluation Agency) for its use in combination with melphalan.<sup>7</sup>

In the ILP system, TNF $\alpha$  is administered in a 10-fold higher dose compared with the maximum tolerable dose in systemic administration. The maximum tolerable dose of TNF $\alpha$  in single-dose intravenous or intramuscular administration is limited by toxicity at 400  $\mu\text{g}/\text{m}^2$ .<sup>8,9</sup> Toxicity consists of fever, hypotension, chills, and transient leukopenia. Hardly any tumor response has been reported after systemic administration of TNF $\alpha$ .<sup>9-11</sup>

Despite careful precautions, systemic leakage of more than 10% appeared in 10 patients during the last 6 years in our hospital. These patients had a remarkably mild clinical course. To get more insight into the cause of this discrepancy between the high systemic concentration of TNF $\alpha$  and the mild clinical symptoms, we studied cytokine levels and the acute phase response.

## PATIENTS AND METHODS

### Patients

From the 212 patients who underwent an ILP with TNF $\alpha$  and melphalan in the past 8 years in our hospital, 10 patients were selected because of very high systemic levels of TNF $\alpha$  caused by leakage from the perfusate. These patients were treated because of an irresectable sarcoma ( $n = 6$ ) or melanoma with multiple in-transit metastases ( $n = 4$ ). Demographic and treatment characteristics are summarized in Table 1. As a control group, we studied nine comparable patients undergoing ILP without systemic leakage. These patients were all sarcoma patients, who underwent a 90-minute ILP with 3 to 4 mg of TNF $\alpha$ . The mean age was 48 years (range, 21-77 years).

### Treatment Schedule

The procedure of ILP has been described previously.<sup>5</sup> In brief, ILP consisted of a 90-minute-long perfusion with 3 to 4 mg of recombinant human TNF $\alpha$  (Boehringer Ingelheim, Alkmaar, The Netherlands) and 10 to 13 mg/liter perfusion tissue of melphalan (Alkeran; Burroughs Wellcome, London, UK) at mild hyperthermia (39°C to 40°C). Composition of the perfusate was as follows: priming volume of 700 to 850 ml consisted of 400 to 500 ml of blood (50% red blood cells/50% plasma), 200 to 400 ml of 5% dextran-40 in glucose 5% (Isodex; Pharmacia, Uppsala, Sweden), 10 to 30 ml of 8.4% sodium bicarbonate, and 0.5 ml of 2500 to 5000 IU heparin. TNF $\alpha$  was injected as a bolus into the arterial line if limb tissue temperature was  $>38^\circ\text{C}$ . Melphalan was administered 30 minutes later at limb temperatures between 39°C to 40°C. At the end of perfusion, the limb was washed with at least 2 liters of 6% dextran-70 (Macrodex; Pharmacia). During and after ILP, vital signs of the patients, including body temperature, heart rate, blood pressure, and fluid balance, were recorded. Toxicity was registered according to the World Health Organization criteria.<sup>12</sup>

### Leakage Monitoring

During ILP, there was a dynamic balance between two pressure compartments, the systemic vasculature and the isolated circuit, which could be influenced by adjusting the systemic blood pressure and/or the extracorporeal flow rate. Throughout the perfusion period, any potential leakage of the drugs was monitored by using a radioactive tracer. A small calibration dose of human serum albumin radiolabeled with iodine 131 or technetium 99m was injected into the systemic circulation and a 10-fold higher dose of the same isotope into the isolated extremity. Continuous monitoring was performed with a precordial scintillation probe. Systemic leakage was ex-

TABLE 1. Patient characteristics

Patient no.	Age, y	Sex	Diagnosis	Arm/leg	Duration of perfusion, min	Dose (mg of TNF $\alpha$ )	Leak, %	Maximum systemic TNF (ng/ml)
1	55	F	Sarcoma	Leg	90	2	23	169
2	52	F	Melanoma	Leg	90	4	20	178
3	66	M	Sarcoma	Arm	90	3	12	30
4	61	F	Sarcoma	Arm	30	3	65	277
5	71	F	Melanoma	Leg	90	2	24	112
6	56	M	Sarcoma	Leg	90	2	15	77
7	65	M	Melanoma	Leg	90	2	32	108
8	64	F	Melanoma	Leg	90	4	13	104
9	83	M	Sarcoma	Leg	75	4	19	174
10	55	F	Sarcoma	Leg	90	4	16	90

TNF, tumor necrosis factor.

pressed quantitatively as a percentage such that 100% leakage represented a homogeneous distribution of the isotope in the body.

### Blood Sampling Procedure

Venous blood samples were collected at several time points, i.e., the day before ILP, just before administration of TNF $\alpha$  in the perfusate, halfway perfusion, and just before release of the tourniquet (after completion of the washout procedure at the end of the perfusion); then after ILP, 5, 10, and 30 minutes, and 3 and 7 hours after release of the tourniquet, and once a day until 7 days after ILP. Samples from the perfusate were obtained at the following times: 0 (just before administration of TNF $\alpha$ ) and 10, 30, 60, and 90 minutes after administration of TNF $\alpha$ . Blood samples were immediately centrifuged; plasma was collected and stored at  $-70^{\circ}\text{C}$  until tested.

### Assays for Cytokine and Acute Phase Protein Analysis

Cytokine and acute phase protein (APP) levels were measured by using an enzyme-linked immunosorbent assay (ELISA). Used antibodies were obtained from the Central Laboratory of the Blood Transfusion Service (Amsterdam, The Netherlands). For measuring TNF $\alpha$ , as described previously,<sup>13</sup> flat-bottomed microtiter plates (Nunc, Kamstrup, Denmark) were coated overnight with purified monoclonal antibody (mAb) against TNF $\alpha$  (CLB-TNF/7). After washing, serial dilutions of TNF-containing samples were added. Bound TNF $\alpha$  was detected by biotinylated sheep anti-TNF $\alpha$ . The detection limit of the assay was 5 pg/ml. Healthy controls were at less than 5 pg/ml. The IL-6-specific ELISA has been described previously.<sup>14</sup> A coat of CLB-IL-6/16 was applied overnight, and bound IL-6 was detected by biotinylated affinity-purified polyclonal sheep anti-IL-6. A lower detection limit was 1 pg/ml, and normal healthy control subjects were at less than 10 pg/ml.

For IL-8, a coat of CLB-IL-8/1 mAb was applied overnight and bound IL-8 was detected by biotinylated affinity-purified polyclonal sheep anti-IL-8. The lower detection limit of this assay was 8 pg/ml. Normal values were at less than 20 pg/ml.<sup>15</sup>

C-reactive protein (CRP) levels were measured by a sandwich ELISA, using polyclonal rabbit anti-human CRP Abs as catching Abs and biotinylated mAb anti-CRP (CLB anti-CRP-2) as a detecting Ab. Results were referred to a standard (Behringwerke AG, Marburg, Germany) and expressed as milligrams per liter. The detection limit was 10 ng/liter.<sup>16</sup>

The ELISA used for measuring s-phospholipase A<sub>2</sub> (sPLA<sub>2</sub>) has been described before.<sup>17</sup> Two different mAbs against human sPLA<sub>2</sub> were used as coating and catching antibodies respectively. The lower limit of detection was 0.1 ng/ml. Normal healthy volunteers were at less 5 ng/ml.

### Statistics

Median values are expressed with range. Comparison between the cytokine and APP levels in the two groups (with and without leakage) were made by the Mann-Whitney *U* test. Values of *P* = .05 were considered to be statistically significant.

## RESULTS

### Systemic Toxicity

Ten patients with a systemic leakage percentage of more than 10% were entered onto this study. Leakage varied from 12% to 65% (mean, 24%; Table 1).

Because of expected toxicity, all patients are well monitored at our intensive care unit postoperatively. Systemic toxicity is summarized in Table 2. During ILP, blood pressure and pulse rate remained stable with adequate fluid management. The body temperature did not increase above  $38^{\circ}\text{C}$ . After ILP, all patients received indomethacin to suppress flu-like symptoms. Eight of 10 patients developed fever grade II ( $38^{\circ}\text{C}$  to  $40^{\circ}\text{C}$ ) within

**TABLE 2.** Systemic toxicity after ILP in the 10 patients with leakage to the systemic circulation compared with 9 patients without leakage

	Toxicity (WHO grade)			
	Grade 0-I	Grade II	Grade III	Grade IV
<b>Leakage</b>				
Fever	2	8	0	0
Hypotension	3	3	4	0
Leukocytes <sup>a</sup>	8	0	1	1
Platelets <sup>b</sup>	6	3	0	1
Bilirubin <sup>c</sup>	3	3	4	0
ASAT/ALAT <sup>d</sup>	7	3	0	0
Nausea	8	2	0	0
<b>Nonleakage</b>				
Fever	6	3	0	0
Hypotension	9	0	0	0
Leukocytes	9	0	0	0
Platelets	9	0	0	0
Bilirubin	9	0	0	0
ASAT/ALAT	9	0	0	0
Nausea	8	1	0	0

WHO, World Health Organization; ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase.

<sup>a</sup> Grade III:  $0-1.9 \times 10^9$ /liter; grade IV:  $<1.0 \times 10^9$ /liter.

<sup>b</sup> Grade II:  $50-74 \times 10^9$ /liter; grade IV:  $<25 \times 10^9$ /liter.

<sup>c</sup> Grade II:  $2.6-5 \times \text{N}$ ; grade III:  $5.1-10 \times \text{N}$  (N = upper limit of normal value).

<sup>d</sup> Grade II:  $2.6-5 \times \text{N}$ .

a few hours after ILP (mean maximal temperature, 38.9°C). In the patients without detectable leakage, the mean maximal temperature was 38.1°C. In four leakage patients, the heart rate increased to more than 110 beats per minute (range, 120–132 beats per minute). Four patients had a hypotension, which was not quickly restored to normal values by fluid administration alone, and required additional treatment with dopamine (3–6  $\mu\text{g}/\text{kg}/\text{min}$ ) for 2 to 3 days. From the start of surgery, a mean of 8 liters was administered to the leakage patients during the first 16 hours vs. 5 liters for nonleakage patients. Leukopenia and thrombocytopenia was absent or mild. Grade IV leukopenia and thrombocytopenia in one patient was induced by leakage of melphalan. No transfusion was required. Patients without leakage did not develop hematological toxicity. All leakage patients had a hyperbilirubinemia after 2 days, and the transaminases increased (grade I-II). In the no-leakage group, only 1 patient had a mild hyperbilirubinemia.

No pulmonary or renal toxicity was observed in any patient.

#### Plasma Cytokine and APP Levels

In Fig. 1, median values with ranges were represented for the cytokines TNF $\alpha$  and IL-6 and the APPs CRP and sPLA<sub>2</sub>. Median peak levels of all measured cytokines and APPs in both patient groups, depicted in Table 3, were significantly different (*P* values in Table 3). Because we know the curves of IL-8 and sPLA<sub>2</sub> from previous published experiments,<sup>18,19</sup> we restricted the determinations to the preoperative and the maximum level time points.

In the leakage group, very high circulating concentrations of TNF $\alpha$  are found during perfusion (at –45 minutes), in contrast to the nondetectable TNF $\alpha$  levels in patients without leakage. Plateau circulating concentrations are measured at the end of the perfusion, lasting up to 30 minutes after ILP. The small amount of TNF $\alpha$  that remains in the limb after the washout procedure does not increase the colossal systemic levels any further in these patients, in contrast to what is observed in patients without leakage. There we observed a brief peak of systemic levels more than 100-fold less than in leakage patients. Moreover, the peak occurs typically at 5 to 10 minutes after ILP and represents the TNF $\alpha$  that was left behind in the limb after the washout. TNF levels decreased already after 30 minutes, because rapid clearance of this cytokine with a short half-life time of 17 minutes is operational. Thus, in leakage patients, very high TNF concentrations are present for about 4 hours, whereas a very short peak of 20 to 30 minutes of “moderate” increased TNF levels is present in leakage-free patients. There was a strict

correlation between the degree of leakage estimated by isotope monitoring, the (adjusted) dose of TNF $\alpha$ , and the measured maximum systemic levels of TNF $\alpha$ , depicted in Table 1.

IL-6 increased already during perfusion in leakage patients, immediately induced by TNF $\alpha$ . In the nonleak patients, IL-6 increased 5 to 10 minutes after ILP, i.e., after TNF $\alpha$  from the washed out limb appeared in the systemic circulation. Maximum values of IL-6 were reached 3 hours after ILP. IL-8 showed the same pattern as IL-6 (data not shown). In the control group, values of IL-6 and IL-8 were 10 to 60 times lower than in the leakage patients.


The APP CRP was increased from 3 hours after ILP until more than 7 days after ILP. Peak levels occurred at day 1. The CRP curve in patients without leakage was comparable, but the peak value was higher. Levels of sPLA<sub>2</sub> were very different for each patient. However, the pattern was consistent, with the start of the increase at 3 hours after ILP and the peak at day 1. Levels were still increased after 7 days. Levels in the nonleakage patients were factor 6 lower.

#### Levels of Cytokines and APPs in Perfusate

No significant difference was observed in perfusate levels of cytokines and APPs in patients who underwent ILP with systemic leakage and without leakage. From the ILP patients with systemic leakage, only five series of perfusate samples were available. Curves are presented in Fig. 2. TNF levels remained stable at approximately 7.5  $\mu\text{g}/\text{ml}$ . IL-6 increased after 10 minutes of perfusion, to 4.3 ng/ml at the end of perfusion. IL-8 increased from 65 to 1600 pg/ml during perfusion. CRP did not change during perfusion, with values hardly detectable or at less than the detection limit. In three of five patients, sPLA<sub>2</sub> increased during perfusion; the median value at the end of perfusion was 14 ng/ml and the range, 8.5 to 266 ng/ml.

## DISCUSSION

The aim of our study was to quantify cytokine levels and acute phase response in patients who underwent an ILP with high-dose TNF $\alpha$  complicated by high leakage, compared with the same variables in patients without leakage, and correlate findings with clinical toxicity. In this study, we measured TNF $\alpha$  plasma levels up to 277 ng/ml. Nevertheless, most of the patients needed only extra intravenous fluid administration. Systemic levels of this magnitude have been described before in the same setting<sup>20,21</sup> and once after a 30-minute intravenous infusion of recombinant TNF $\alpha$ .<sup>22</sup>



**FIG. 1.** Median (with range) of tumor necrosis factor (TNF) (A), interleukin (IL)-6 (B), and C-reactive protein (CRP) and s-phospholipase A<sub>2</sub> (sPLA<sub>2</sub>) (C) in plasma from 10 patients who underwent an isolated limb perfusion (ILP) complicated by high leakage (>12%) to the systemic blood circulation. For TNF (◇; A), IL-6 (□; B), and CRP (○; C), the curves of the nonleakage group are also depicted. Time points were as follows: pre, preoperative; 0', just before perfusion; -45', halfway perfusion; -1', just before release of the tourniquet; 5' (10' and 30'), 5 (10 and 30) minutes after release of the tourniquet; 3h and 7h, 3 and 7 hours after ILP; d1 to d7, number of days after ILP.

**TABLE 3.** Median and range of peak levels of cytokines and acute phase proteins in 10 patients undergoing ILP with more than 10% leakage compared with 9 patients without leakage in the systemic circulation

Cytokine/acute phase protein	Time point	Leakage patients, median (range)	No leakage, median (range)	P
TNF $\alpha$ , ng/ml	10 min after ILP	108 (26–277)	1.4 (0.3–3.4)	<.001
IL-6, ng/ml	3 h after ILP	49 (13–257)	0.8 (0.3–3.3)	<.001
IL-8, ng/ml	3 h after ILP	14 (1.3–49)	0.2 (0.01–1.7)	<.001
CRP, mg/l	Day 1	76 (34–419)	166 (93–350)	<.01
sPLA <sub>2</sub> , ng/ml	Day 1	568 (123–986)	84 (20–390)	<.01

ILP, isolated limb perfusion; TNF $\alpha$ , tumor necrosis factor- $\alpha$ ; IL-6 and IL-8, interleukin-6 and interleukin-8; CRP, C-reactive protein; sPLA<sub>2</sub>, s-phospholipase A<sub>2</sub>.

In our patients, the necessity for dopamine administration was not related to the highest levels of TNF $\alpha$  in the systemic circulation. This finding is in accordance with previous studies in which no correlation between maximum TNF $\alpha$  concentrations in the peripheral blood of an individual and the side effects could be found,<sup>20,23</sup> which indicates that patients vary in their sensitivity to TNF $\alpha$ .


Systemic toxicity seems to be determined by the duration of exposure to high levels of TNF $\alpha$ . Our data demonstrate this clearly, with levels of 1,000 to more than 100,000 pg/ml for 4 hours in high leakage patients, and only “moderate” levels (~1,000 pg/ml for 20 minutes) in nonleakage patients. In nonleakage patients, 20 minutes of “moderate” TNF levels were not enough to cause hypotension. This is in accordance with the findings reported previously in this journal by Vrouenraets et al.,<sup>24</sup> who described minimal toxicity after leakage-controlled ILP in 20 patients. The IL-6 curves demonstrate the effect of prolonged exposure to high TNF levels even more pungently. Even at 24 hours after ILP, IL-6 levels are still higher in the leakage patients than the peak IL-6 levels observed in ILP patients without leakage. IL-6 levels remained elevated for at least 3 whole days.

In the 10 patients with high leakage, 4 hours of exposure to very high levels of TNF $\alpha$  resulted in three patients with grade II and four patients with grade III hypotension. Four patients required dopamine support temporarily with good response. In phase I–II studies on the systemic administration of TNF $\alpha$ , dose-limiting toxicity was observed at TNF concentrations similar to those observed in our 10 patients described here. For instance, Schaadt et al.<sup>22</sup> reported dose-limiting hypotension in 32% of the patients after administration of 650  $\mu$ g/m<sup>2</sup> intravenously, resulting in a systemic TNF peak concentration of approximately 270 ng/ml. Moreover, grade II hepatotoxicity was observed in 80% of the patients. This is quite different from the relative lack of toxicity observed in our 10 ILP patients who had similar systemic TNF peak concentrations. In other studies, hy-

potension was dose limiting at lower doses, with serum TNF levels of 10 ng/ml.<sup>8,9</sup>

In comparison with septic shock, the duration of exposure to elevated levels of TNF $\alpha$  in the leakage patients is relatively short. The prolonged exposure in septic shock, despite concentrations many times lower than the short peak levels after ILP, results in the typically unresponsiveness of the hypotension to fluid challenge in the septic shock patients.<sup>25–28</sup> Adequate diuresis plays a key role to keep the period of high circulating TNF levels as short as possible, to prevent a septic shock-like state in perfusion patients. That patients are well hydrated at the time of exposure to TNF, and that their blood pressure is optimally maintained by fluid challenge, and only if necessary also by the use of dopamine, prevents a septic shock-like situation. This explains why these patients have little toxicity in view of the very high circulating TNF levels. It is a fundamental difference, with often poorly hydrated patients with metastatic cancer who received intravenous TNF $\alpha$  in phase I–II studies in the past. Moreover, septic patients are infected and have significant levels of endotoxin, which has been shown to be synergistic with TNF $\alpha$  for toxicity (in rats).<sup>29,30</sup> In addition, Feelders et al.<sup>31</sup> have shown that, in patients who underwent ILP, cortisol is already increased before the TNF peak as a result of surgery and anesthesia. The cortisol response may have a down-regulatory effect on TNF $\alpha$ .

The increased TNF $\alpha$  levels in the patients with systemic leakage were followed by significantly higher levels of IL-6 and IL-8. This is in accordance with previous studies.<sup>18,20,32</sup> In our study, we also determined CRP and sPLA<sub>2</sub> as variables of the acute phase response. sPLA<sub>2</sub> levels were more increased in the leakage patients; CRP, in contrast, had significantly lower levels in these patients at the time points of maximum values. Lower levels of CRP than expected were also observed in patients who underwent an isolated hepatic perfusion.<sup>33</sup> That CRP had even lower levels in leakage patients could be ascribed to a higher expenditure of CRP in the



**FIG. 2.** Median (with range) of cytokine (A) and acute phase protein (B) profile in perfusate from five patients who underwent an isolated limb perfusion complicated by high leakage (>12%) to the systemic blood circulation. Time points were as follows: 0', just before administration of tumor necrosis factor (TNF) in the perfusate; 10' (30' and 60'), 10 (30 and 60) minutes after start of perfusion; 90', end of perfusion, just before release of the tourniquet. IL-6, interleukin-6; CRP, C-reactive protein; sPLA<sub>2</sub>, s-phospholipase A<sub>2</sub>.

neutralization of the effects of exposure to higher levels of TNF $\alpha$ .<sup>34-36</sup>

In conclusion, ILP, complicated by high leakage to the systemic circulation, resulted in high systemic levels of TNF $\alpha$  up to 277 ng/ml. IL-6 and IL-8 followed with significantly higher levels compared with values measured in patients without leakage. The patterns of the APPs CRP and sPLA<sub>2</sub> resembled each other, except that CRP had significantly lower maximum levels in leakage patients compared with patients without leakage. Overall, the patients with high systemic leakage had a marked mild clinical course. It is our experience that, even in patients with very high leakage, life-threatening reactions have not occurred and that temporary hypotension can be easily dealt with by fluid challenge and some-

times by temporary vasopressor support. Our observations support the need for further study of the potential use of TNF $\alpha$  systemically.

## REFERENCES

1. Creech OJ, Kremenz ET, Ryan RF, Winblad JN. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit. *Ann Surg* 1958;148:616-32.
2. Eggermont AMM. Treatment of melanoma-in-transit metastases confined to limb. *Cancer Surv* 1996;26:335-49.
3. Liénard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ. High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. *J Clin Oncol* 1992;10:52-60.
4. Liénard D, Eggermont AMM, Schraffordt Koops H, et al. Isolated perfusion of the limb with high dose tumor necrosis factor-alpha

- (TNF $\alpha$ ) and interferon-gamma (IFN $\gamma$ ) and melphalan for melanoma stage III: results of a multi-center pilot study. *Melanoma Res* 1994;4:21–6.
5. Eggermont AMM, Schraffordt Koops H, Liénard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor- $\alpha$  in combination with interferon- $\gamma$  and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. *J Clin Oncol* 1996;14:2653–65.
  6. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. *Ann Surg* 1996;274:756–65.
  7. Eggermont AMM, Schraffordt Koops H, Klausner JM, et al. Limb salvage (LS) by isolated limb perfusion (ILP) with TNF and melphalan (M) in 246 patients with advanced soft tissue sarcomas (STS): results of 270 ILPs in 246 patients [Abstract]. *Proc Am Soc Clin Oncol* 1999;18:A2067.
  8. Selby P, Hobbs S, Viner C, et al. Tumor necrosis factor in man: clinical and biological observations. *Br J Cancer* 1987;56:803–8.
  9. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase-I trial of intravenously administered recombinant tumor necrosis factor alpha in cancer patients. *J Clin Oncol* 1988;6:1328–34.
  10. Wiedenmann B, Reichardt P, R  th U, et al. Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas. *Cancer Res Clin Oncol* 1989;115:189–92.
  11. Gamm H, Lindemann A, Mertelsmann R, Hermann F. Phase I trial of recombinant human tumor necrosis factor alpha in patients with advanced malignancy. *Eur J Cancer* 1991;27:856–63.
  12. World Health Organization. *Handbook for Reporting Results of Cancer Treatment*. Geneva: WHO Offset Publications, 1979.
  13. Van Kooten C, Rensink I, Pascal-Salcedo D, Van Oers R, Aarden LA. Monokine-production by human T-cells: IL-1 $\alpha$  production restricted to memory T-cells. *J Immunol* 1991;146:2654–8.
  14. Helle M, Boeijs L, De Groot ER, De Vos A, Aarden LA. Sensitive ELISA for interleukin 6: detection of IL-6 in biological fluids and sera. *J Immunol Methods* 1991;138:42–56.
  15. Verbrugh CA, Hart MH, Aarden LA, Swaak AJG. Interleukin-8 (IL-8) in synovial fluid of rheumatoid and nonrheumatoid joint effusions. *Clin Rheumatol* 1993;12:494–6.
  16. Wolbink GJ, Brouwer MC, Buysmann S, ten Berge IJM, Hack CE. CRP-mediated activation of complement in vivo: assessment by measuring circulating complement-C-reactive protein complexes. *J Immunol* 1996;157:473–9.
  17. Wolbink GJ, Schalkwijk C, Baars JW, Wagstaff J, Van den Bosch H, Hack CE. Therapy with interleukin-2 induces the systemic release of phospholipase-A<sub>2</sub>. *Cancer Immunol Immunother* 1995;41:287–92.
  18. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. *J Clin Oncol* 1995;13:264–73.
  19. Ogilvie AC, Wolbink GJ, Rankin EM. Release of secretory phospholipase A<sub>2</sub> during isolated limb perfusion with tumor necrosis factor- $\alpha$ : relation to clinical and inflammatory parameters. In: Ogilvie AC, ed. *The Inflammatory-Coagulative Response During Treatment With Biological Response Modifiers* [thesis]. Amsterdam: Free University, 1995:95–114.
  20. G  rain J, Li  nard D, Ewalenko P, Lejeune FJ. High serum levels of TNF- $\alpha$  after its administration for isolation perfusion of the limb. *Cytokine* 1992;4:585–91.
  21. Eggimann P, Chiol  ro R, Chassot PG, Li  nard D, G  rain J, Lejeune FJ. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. *Chest* 1995;107:1074–82.
  22. Schaadt M, Pfreundschuh M, Lorscheidt G, Peters KM, Steinmetz T, Diehl V. Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma. *J Biol Response Mod* 1990;9:247–50.
  23. Lejeune FJ, Li  nard D, Eggermont AMM, et al. Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of melanoma. *Circ Shock* 1994;43:191–97.
  24. Vrouenraets BC, Kroon BBR, Ogilvie AC, et al. Absence of severe toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor- $\alpha$  and melphalan. *Ann Surg Oncol* 1999;6:405–12.
  25. Dofferhoff AS, Bom VJ, De Vries-Hospers HG, et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute-phase proteins during the treatment of severe sepsis in humans. *Crit Care Med* 1992;20:185–92.
  26. Hack CE, Aarden LA, Thijs LG. Role of cytokines in sepsis. *Adv Immunol* 1997;66:101–95.
  27. Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution (tumor necrosis factor-alpha and interleukin-6) after septic shock, hemorrhagic shock, and severe trauma. *Crit Care Med* 1997;25:1813–9.
  28. Avontuur JAM, Stam TC, Jongen-Lavrencic M, Van Amsterdam JGC, Eggermont AMM, Bruining HA. Effect of L-NAME, an inhibitor of nitric oxide synthesis, on plasma levels of IL-6, IL-8, TNF- $\alpha$  and nitrite/nitrate in human septic shock. *Intensive Care Med* 1998;24:673–9.
  29. Neilson IR, Neilson KA, Yunis EJ, Rowe MI. Failure of tumor necrosis factor to produce hypotensive shock in the absence of endotoxin. *Surgery* 1989;106:439–43.
  30. Ciancio MJ, Hunt J, Jones SB, Filkins JP. Comparative and interactive in vivo effects of tumor necrosis factor alpha and endotoxin. *Circ Shock* 1991;33:108–20.
  31. Feelders RA, Swaak AJG, Romijn JA, et al. Characteristics of recovery from the euthyroid sick syndrome induced by tumor necrosis factor alpha in cancer patients. *Metabolism* 1999;48:324–9.
  32. G  rain J, Li  nard D, Pampallona S, et al. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. *Cytokine* 1997;9:1034–42.
  33. De Vries MR, Borel Rinkes IHM, Swaak AJG, et al. Acute-phase response patterns in isolated hepatic perfusion with tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) and melphalan in patients with colorectal liver metastases. *Eur J Clin Invest* 1999;29:553–60.
  34. Heuertz RM, Webster RO. Role of C-reactive protein in acute lung injury. *Mol Med Today* 1997;3:539–45.
  35. Hack CE, Wolbink GJ, Schalkwijk C, Speijer H, Hermens WT, van den Bosch H. A role for secretory phospholipase A<sub>2</sub> and C-reactive protein in the removal of injured cells. *Immunol Today* 1997;18:111–5.
  36. Szalai AJ, Agrawal A, Greenhough TJ, Volanakis JE. C-reactive protein: structural biology, gene expression, and host defense function. *Immunol Res* 1997;16:127–36.